IRB #

STUDY00016890

Title

A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma

Principal Investigator

Eric Anderson

Study Purpose

The purpose of this study is to compare any good and bad effects of using of using BBI-608, in combination with the usual chemotherapy regimen, nab-paclitaxel and gemcitabine in participants with metastatic pancreatic cancer.

Medical Condition(s)

Metastatic Pancreatic Cancer

Eligibility Criteria

≥ 18 years of age
metastatic pancreatic cancer

Age Range

18 - 120

Healthy Volunteers Needed

No

Duration of Participation

If you are randomized to the study drug, you may continue to receive the study drug until your disease worsens or if you have bad side effects.

Minors Included

No

Contact

Knight Cancer Institute Clinical Trials
trials@ohsu.edu
503 494-1080

Sponsor

Boston Biomedical, Inc

Recruitment End

12/20/2020

Compensation Provided

No


Go Back